Industrials and Cyclical Valuation: Mid-Cycle Normalization

Introduction

Cyclical companies are among the most commonly mispriced assets in finance, and the error almost always stems from applying standard valuation tools without adjusting for the cycle. When a steel company reports record EBITDA during an infrastructure boom, its trailing EV/EBITDA multiple looks cheap. When the same company's EBITDA collapses during a recession, its multiple looks impossibly expensive. In both cases, the market is pricing the stock based on a temporary earnings level, not a sustainable one. Mid-cycle normalization corrects for this by estimating what the company would earn under normal economic conditions.

This concept applies broadly across industrials, materials, chemicals, transportation, construction, aerospace and defense, and any sector where demand and pricing are sensitive to the macroeconomic cycle.

The Peak-Cycle Trap

At the peak of the cycle, earnings are high and multiples appear low. An investor or acquirer looking at trailing EV/EBITDA sees what looks like a cheap company. But the "cheap" multiple is misleading because the denominator (EBITDA) is inflated by unsustainable pricing, high capacity utilization, and strong demand. When the cycle turns, EBITDA declines, the multiple expands (on lower earnings), and the investor discovers they paid a fair multiple on peak earnings, which is equivalent to overpaying on a normalized basis.

The Trough-Cycle Trap

At the bottom of the cycle, the opposite occurs. Earnings are depressed, multiples appear stretched (or EBITDA may be negative), and the company looks "expensive." But this is precisely when the company may be most attractive: the underlying assets have not disappeared, and earnings will recover when the cycle turns. Selling at the trough because the multiple looks high is the mirror image of buying at the peak because it looks low.

Method 1: Historical Average EBITDA

The simplest approach: calculate the average EBITDA over a full economic cycle (typically 5-7 years, covering both expansion and contraction). This average approximates the mid-cycle earning power of the business.

If a chemical company's EBITDA over the past 7 years was $300M, $400M, $500M, $600M, $450M, $350M, $280M, the average is approximately $411M. This average is a reasonable estimate of mid-cycle EBITDA, regardless of where the company currently sits in the cycle.

Limitation: The historical average assumes the company's earning power has not structurally changed. If the company has made significant acquisitions, entered new markets, or improved its cost structure, the historical average may understate its current normalized earnings.

Method 2: Average Return on Invested Capital

Calculate the company's average ROIC over a full cycle, then apply it to the current invested capital base to estimate normalized earnings. This method accounts for changes in the company's size and capital base while normalizing the return.

This approach is more sophisticated but requires clean data on invested capital and may be distorted by accounting changes or large impairments.

Method 3: Cycle Position Adjustment

If the analyst can estimate where the company currently sits in the cycle (early recovery, mid-cycle, late-cycle peak, downturn), they can adjust the current EBITDA toward its mid-cycle level. This requires judgment about cycle duration and the company's sensitivity to the cycle.

Mid-Cycle EBITDA

An estimate of the EBITDA a cyclical company would generate under normal, mid-cycle economic conditions, abstracting away from temporary peaks or troughs. Mid-cycle EBITDA is used as the denominator in valuation multiples (producing a "mid-cycle EV/EBITDA" that reflects sustainable value rather than a point-in-time distortion) and as the base year for DCF projections. The two primary estimation methods are the historical average EBITDA over a full cycle (5-7 years) and the average ROIC applied to the current capital base.

Once mid-cycle EBITDA is estimated, the analyst applies a mid-cycle EV/EBITDA multiple from the peer group. Critically, the peer group multiples should also be calculated on a mid-cycle basis (or, if calculated on trailing data, the analyst must acknowledge that the peer group may be at a different cycle position than the target).

For context, industrial EV/EBITDA multiples in the current environment (2025-2026) range from approximately 8-12x for general manufacturing and distribution, 12-16x for specialty industrials with technology content, and 16-18x for aerospace and defense (where government contracts provide revenue visibility). The S&P 500 industrials average is approximately 12x.

Aerospace and Defense

A&D is less cyclical than general industrials because government defense spending provides a baseline of predictable revenue. However, the commercial aerospace portion (aircraft OEM suppliers, MRO providers) is highly cyclical, tied to airline capex cycles and passenger demand. In 2025, A&D valuations reached 16-18x EBITDA (median), significantly above the broader industrials complex (~12x), driven by record defense budgets and the post-pandemic commercial aviation recovery.

Chemicals

Chemical companies are among the most cyclical in the industrial universe because their products are commodities with prices determined by global supply-demand dynamics. Mid-cycle normalization is essential: a specialty chemical company might trade at 6x peak EBITDA and 15x trough EBITDA, but its through-cycle multiple is approximately 9-10x.

Transportation and Logistics

Trucking, shipping, and rail are cyclical businesses tied to trade volumes and economic activity. Asset-heavy segments (shipping, rail) require additional consideration of asset values (fleet, rolling stock) alongside earnings-based metrics.

Through-Cycle Multiple

The EV/EBITDA multiple applied to a cyclical company's mid-cycle normalized EBITDA to derive a through-cycle valuation. The through-cycle multiple itself should reflect the company's average trading multiple across a full business cycle, not the multiple at the current point in the cycle. At a cyclical peak, the trailing EV/EBITDA appears low (high EBITDA inflates the denominator), making the company look cheap when it is actually most expensive. At a trough, the trailing multiple appears high (low EBITDA deflates the denominator), making it look expensive when it may be cheapest. The through-cycle approach, pairing a mid-cycle EBITDA with a mid-cycle multiple, avoids both traps and produces a more stable valuation that can be compared across periods and across companies at different points in their cycles.